CA-PATIENT-SAFETY
23.11.2020 14:02:03 CET | Business Wire | Press release
Every year, more than 4.8 million patients lose their lives to preventable medical errors worldwide. The Patient Safety Movement Foundation (PSMF) , a global non-profit, is committed to achieving zero preventable patient deaths by 2030 and has launched a revised commitment model for hospitals and healthcare organizations to help make its goal a reality.
The Patient Safety Movement Foundation’s initial model focused on securing healthcare organization commitments to target the leading causes of preventable harm and death occurring in healthcare facilities. Today’s updates instead ask organizations to commit to building and sustaining a foundation for safe and reliable care – and provide free “Actionable Patient Safety Solutions” (APSS), which include evidence-based best practice summaries and solutions, educational resources and virtual coaching to help organizations integrate these best practices into their existing processes.
“Under our previous commitment model, our hospital and health system partners reported that they saved 366,353 lives between 2012-2020 – showing that committing to implementing processes to prevent medical harm and deaths does save lives,” said David B. Mayer, MD, CEO of Patient Safety Movement Foundation. “But to reach our ultimate goal of zero, we realized it was time for a different approach with an emphasis on creating a foundation for safety. This is where we see gaps in implementation globally and we have to help healthcare organizations focus on the basics.”
The Patient Safety Movement Foundation will concentrate on three critical components: a person-centered culture of safety; a holistic and continuous improvement framework; and an effective model for sustainment. Its interdisciplinary global leaders have created APSS Blueprints , APSS Education and virtual APSS Coaching . The APSS Blueprints are best-practice summaries leveraging the latest evidence for performance improvement around a variety of topics like healthcare-associated infections, medication safety and even mental health. APSS Education includes videos, webinars and articles to enhance the APSS Blueprints. Finally, APSS Coaching ties it all together with skilled consultants partnering alongside healthcare organizations to walk them through the specifics of how to navigate improving their processes. Together, these offerings complement one another to create a powerful tool for hospitals to use to improve their care.
“The virtual coaching services we offer to our committed healthcare organizations typically cost hundreds of thousands or even millions of dollars, but we believe that if we truly want to eliminate harm from preventable medical errors, these services should be free,” stated Donna Posser, DNP, RN, NE-BC, FACHE, BCPA, chief clinical officer at Patient Safety Movement Foundation. “We have developed this material and enhanced our clinical support services to help remove barriers to adoption and make it even easier and more cost-effective for hospitals, long-term care facilities, ambulatory surgery centers, primary care clinics and beyond to reinvent their systems and implement proven measures for increasing patient and staff safety.”
Committed hospital and healthcare organization partners will also be asked to share performance data, including the number of serious safety events, precursor events and near misses on an annual basis, which will be kept private and shared only as aggregated data combined from organizations across the globe to showcase the proven positive impact of this model on patient safety outcomes.
To learn more about how to make a commitment, visit https://patientsafetymovement.org/partners/commitments/commitment-faqs/ . To access the free clinical services and products offered, visit https://patientsafetymovement.org/clinical-support-products-and-services/ .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Its Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors and its Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org to learn more, and follow PSMF on Linkedin , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005481/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
